Madrigal Pharmaceuticals signed an exclusive licensing agreement with Suzhou Ribo Life Science and Ribocure for six preclinical siRNA programs targeting metabolic dysfunction-associated steatohepatitis (MASH). Madrigal paid $60 million upfront with potential milestones driving the deal to as much as $4.4 billion, and the company will fund development and commercialization worldwide. Madrigal framed the acquisition as a strategy to broaden its therapeutic approaches around Rezdiffra, its approved MASH medicine, by adding highly liver‑targeted RNAi assets. The deal highlights continued industry appetite to pair symptomatic or metabolic modulators with genetic knockdown approaches in liver disease and shows growing deal flow from China-based discovery partners into Western biopharma.